As clinical trials reveal more evidence for the therapeutic potential of psychedelic drugs such as psilocybin, DMT, and even entheogens like MDMA, many psychedelic companies have sprung up to develop psychedelic drugs for specific applications. With promising results in the treatment of mental health conditions such as depression, addiction, anxiety, and more, investment interest in this fledgling industry is building.
In this webinar, Tim Schildt explains important considerations regarding investing in psychedelic companies, expectations as the industry grows, and the role that non-profits will continue to play.
With experience as an Investment Banker at J.P. Morgan and Greenhill, as well as a Private Equity Investor at Madison Dearborn Partners, Tim Schildt brings years of knowledge investing across life sciences and healthcare services.
Tim co-founded Palo Santo with a belief that access to, and costs of, psychedelic medicines will be the greatest pain point for patients. His primary mission is to invest in companies and solutions that allow for broad access to those most in need of mental health care.
He has held a lifelong passion for understanding and improving treatments for CNS disorders and believes psychedelics are poised to shift the paradigm in mental health treatment.
Drug Science is the leading independent scientific body on drugs in the UK. We rely on donations to provide clear, evidence-based information without political or commercial interference. Drug Science webinars are free, so if you’d like to support us then please consider joining the Drug Science Community.